Luis Robles

Luis Robles

Auto-generated profile, based on publicly available information

Luis Robles

Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in Revista Española de Enfermedades Digestivas
Verified
Journal Article
Open access
PDF file
JPJosé Perea
José Perea
IJIago Justo
Iago Justo
EÁE. Álvaro
E. Álvaro
MLM. Lomas
M. Lomas
JTJ. Díaz Tasende
J. Díaz Tasende
MHM. Hidalgo
M. Hidalgo
The importance of colorectal cancer (CRC) is increasing. A proportion show a hereditary component, as in Lynch syndrome and Familial Adenomatous Polyposis, and a recently defined entity as well, namely, Familial Colorectal Cancer type X. The high probability to develop CRC in these groups may, at the time of recognition, change surgical management, including its timing or even the surgical technique. In some cases prophylactic surgery can play an important role. The possibility of using tools that allow recognition of the aforementioned syndromes, including microsatellite instability, immunohistochemistry for DNA mismatch repair system proteins, and especially their mutations, is on the basis of therapeutic strategies that differ from those employed in sporadic CRC cases.

2 December 2014 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
PDF file
LZLeslie Zevallos
Leslie Zevallos
VSValerio Salas
Valerio Salas
LRLuis Robles
Luis Robles
Asociaciones público-privadas para servicio de salud: ¿la solución al sistema de salud peruano?

1 May 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MBManuel Benavides
Manuel Benavides
AGAuxiliadora Gómez-España
Auxiliadora Gómez-España
PGPilar García-Alfonso
Pilar García-Alfonso
CGCristina García González
Cristina García González
JVJose María Viéitez
Jose María Viéitez
EAEnrique Aranda
Enrique Aranda

1 July 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
MKMarta Kamieniak
Marta Kamieniak
IMI. Muñoz-Repeto
I. Muñoz-Repeto
JGJesus García-Donas
Jesus García-Donas
LRL. Robles
L. Robles
TCTeresa Ramon y Cajal
Teresa Ramon y Cajal
MGM.J. García
M.J. García

17 November 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MFMERCEDES SALGADO FERNANDEZ
MERCEDES SALGADO FERNANDEZ
JCJuan de la Camara-Gómez
Juan de la Camara-Gómez
IGIgnacio García-Escobar
Ignacio García-Escobar
RÁRenata-Carola Álvarez-Llosa
Renata-Carola Álvarez-Llosa
PGPaula González-Villarroel
Paula González-Villarroel
AMAndres J. Muñoz Martín
Andres J. Muñoz Martín
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. CRC leads to increased activation of the clotting system. Since CRC patients present a higher rate of bleeding, careful evaluation of the risk/benefits of anticoagulant prophylaxis is necessary. To evaluate low molecular weight heparin (LMWH) for primary thromboprophylaxis in metastatic CRC outpatients receiving first-line systemic cancer therapy. PROTINCOL (NCT05625932) is a randomized, open-label (PROBE), multicenter study. Patients will receive tinzaparin (75 IU/kg) or no pharmacological prophylaxis for 4 months and will be stratified based on: BRAF/RAS mutation, primary resection tumor and antiangiogenic therapy. The study outcomes will be assessed by a blinded central independent adjudication committee. The primary efficacy endpoints will include the cumulative incidence of any venous thromboembolism (VTE) event (symptomatic or incidental) including symptomatic central venous catheter VTE. Secondary variables will be clinically relevant bleedings, health-related quality of life and the predictive value of validated risk assessment scales of VTE, including the genetic risk score (TIC-ONCO). Our hypothesis is that prophylactic LMWH will reduce the 55% relative risk to an estimated VTE incidence of 13.5%. A total of 526 patients will be required. Risk prediction of chemotherapy-associated VTE is a compelling challenge in oncology, as VTE may result in treatment delays, impaired quality of life, and increased mortality. Patients with a single type of metastatic cancer with a high risk of VTE will be selected for study inclusion. For the first time in ambulatory prophylaxis of cancer-associated thrombosis, a precision medicine approach will be used in a clinical trial. If the individualization of antithrombotic prophylaxis can reduce the complications of outpatient cancer treatment and be cost effective, it would be of great value in the future care of patients with metastatic CRC. NCT05625932. Registered on 15 Nov 2022. The trial started recruitment on March 2023.